deltatrials
Unknown NA INTERVENTIONAL 3-arm NCT04353050

Atypical MOLes and Melanoma Early Detection Study (MoleMed) (MoleMed)

A Multicenter, Ambispective, Low-interventional Clinical Study Evaluating Molecular Genetic Markers for Non-invasive Differential Diagnosis of Benign and Malignant Pigmented Skin and Mucosal Neoplasms

Sponsor: Blokhin's Russian Cancer Research Center

Updated 7 times since 2020 Last updated: Jun 12, 2022 Started: Apr 1, 2020 Primary completion: Jan 1, 2023 Completion: Nov 1, 2023
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT04353050, this NA trial focuses on Dysplastic Nevus Syndrome and Melanoma and remains ongoing. Sponsored by Blokhin's Russian Cancer Research Center, it has been updated 7 times since 2020, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~May 2020 – ~Jan 2021 · 8 months · monthly snapshotRecruiting~Jan 2021 – ~Sep 2021 · 8 months · monthly snapshotRecruiting~Sep 2021 – ~Jul 2022 · 10 months · monthly snapshotRecruiting~Jul 2022 – ~Jul 2024 · 24 months · monthly snapshotRecruiting~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshotUnknown~Sep 2025 – present · 10 months · monthly snapshotUnknown

Change History

7 versions recorded
  1. Sep 2025 — Present [monthly]

    Unknown NA

  2. Sep 2024 — Sep 2025 [monthly]

    Unknown NA

  3. Jul 2024 — Sep 2024 [monthly]

    Unknown NA

    Status: RecruitingUnknown

  4. Jul 2022 — Jul 2024 [monthly]

    Recruiting NA

  5. Sep 2021 — Jul 2022 [monthly]

    Recruiting NA

Show 2 earlier versions
  1. Jan 2021 — Sep 2021 [monthly]

    Recruiting NA

  2. May 2020 — Jan 2021 [monthly]

    Recruiting NA

    First recorded

Apr 2020

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Blokhin's Russian Cancer Research Center
  • Russian Academy of Medical Sciences
Data source: Russian Academy of Medical Sciences

For direct contact, visit the study record on ClinicalTrials.gov .